Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 17.98 0.73% 0.13
HALO closed up 0.73 percent on Friday, January 19, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
5 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical HALO trend table...

Date Alert Name Type % Chg
Jan 19 Calm After Storm Range Contraction 0.00%
Jan 19 Narrow Range Bar Range Contraction 0.00%
Jan 19 NR7 Range Contraction 0.00%
Jan 19 Lower Bollinger Band Walk Weakness 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Lower Bollinger Band Touch Weakness 0.00%
Jan 18 MACD Bearish Centerline Cross Bearish 0.73%
Jan 18 Calm After Storm Range Contraction 0.73%
Jan 18 Lower Bollinger Band Walk Weakness 0.73%
Jan 18 Inside Day Range Contraction 0.73%

Older signals for HALO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.13
52 Week Low 10.79
Average Volume 1,369,145
200-Day Moving Average 15.3909
50-Day Moving Average 19.1702
20-Day Moving Average 19.663
10-Day Moving Average 19.055
Average True Range 0.8264
ADX 23.25
+DI 18.13
-DI 32.73
Chandelier Exit (Long, 3 ATRs ) 18.6508
Chandelier Exit (Short, 3 ATRs ) 19.5892
Upper Bollinger Band 21.4533
Lower Bollinger Band 17.8727
Percent B (%b) 0.03
BandWidth 18.209836
MACD Line -0.2199
MACD Signal Line 0.065
MACD Histogram -0.2849
Fundamentals Value
Market Cap 2.41 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -19.33
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.54
Resistance 3 (R3) 18.50 18.27 18.45
Resistance 2 (R2) 18.27 18.12 18.29 18.42
Resistance 1 (R1) 18.12 18.03 18.20 18.17 18.39
Pivot Point 17.89 17.89 17.93 17.91 17.89
Support 1 (S1) 17.75 17.75 17.82 17.79 17.57
Support 2 (S2) 17.52 17.66 17.54 17.54
Support 3 (S3) 17.37 17.52 17.51
Support 4 (S4) 17.42